Aprea Therapeutics, Inc.
APRE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1,503 | $583 | $0 | $0 |
| % Growth | 157.6% | – | – | – |
| Cost of Goods Sold | $9,364 | $7 | $16,402 | $272 |
| Gross Profit | -$7,861 | $576 | -$16,402 | -$272 |
| % Margin | -523.2% | 98.8% | – | – |
| R&D Expenses | $9,364 | $7,627 | $92,422 | $23,896 |
| G&A Expenses | $6,459 | $8,428 | $20,970 | $13,550 |
| SG&A Expenses | $6,459 | $8,421 | $20,970 | $13,550 |
| Sales & Mktg Exp. | $0 | -$7 | $0 | $0 |
| Other Operating Expenses | -$9,364 | $0 | -$16,402 | -$272 |
| Operating Expenses | $6,459 | $16,048 | $96,990 | $37,175 |
| Operating Income | -$14,320 | -$15,472 | -$113,392 | -$37,446 |
| % Margin | -953% | -2,652.8% | – | – |
| Other Income/Exp. Net | $1,361 | $1,185 | $730 | $319 |
| Pre-Tax Income | -$12,959 | -$14,287 | -$112,662 | -$37,127 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$12,959 | -$14,287 | -$112,662 | -$36,537 |
| % Margin | -862.4% | -2,449.6% | – | – |
| EPS | -2.35 | -3.95 | -1,359.79 | -34.88 |
| % Growth | 40.5% | 99.7% | -3,798.5% | – |
| EPS Diluted | -2.35 | -3.95 | -1,359.79 | -34.88 |
| Weighted Avg Shares Out | 5,510 | 3,618 | 83 | 1,064 |
| Weighted Avg Shares Out Dil | 5,510 | 3,618 | 83 | 1,064 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,289 | $1,224 | $449 | $2 |
| Interest Expense | $0 | $0 | $449 | $0 |
| Depreciation & Amortization | $22 | $7 | $4 | $272 |
| EBITDA | -$14,297 | -$14,280 | -$37,368 | -$36,856 |
| % Margin | -951.5% | -2,448.4% | – | – |